Kineta Gestione

Name: Approfondimenti finanziari basati su S&P Global Market Intelligence
Creator: Simply Wall St Pty Ltd
License: https://www.spglobal.com/content/dam/spglobal/corporate/en/documents/secure/MI-FastTrack-Terms-and-Conditions-July-2023.pdf

Gestione criteri di controllo 1/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	no data
Proprietà del CEO	n/a
Durata media del management	2yrs
Durata media del Consiglio di amministrazione	2yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Kineta non ha un CEO, o non abbiamo dati su di loro.

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Craig Philips	President & Secretary	2yrs	US$993.40k	0.78% $ 72.5k
Keith Baker	Chief Financial Officer	2yrs	US$813.69k	0.14% $ 12.8k
Thierry Guillaudeux	Chief Scientific Officer	2yrs	Nessun dato	0.18% $ 16.5k
Gary Gentges	Executive Vice President of Corporate Development	no data	Nessun dato	Nessun dato
Pauline Kenny	Advisor	less than a year	US$741.73k	0.15% $ 14.0k

2.0yrs

Durata media

56.5yo

Età media

Gestione esperta: Il team dirigenziale di KANT è considerato esperto (durata media dell'incarico 2 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
David Arkowitz	Independent Director	2yrs	US$141.55k	0.023% $ 2.1k
Kimberlee Drapkin	Independent Director	1.5yrs	US$69.85k	0% $ 0
Shawn P. Iadonato	Chairman of the Board	2yrs	US$1.28m	5.61% $ 522.9k
Raymond Bartoszek	Independent Director	2yrs	US$86.37k	14.68% $ 1.4m
Marion Foote	Independent Director	2yrs	US$90.12k	1.17% $ 108.8k
Scott Dylla	Independent Director	1.5yrs	US$66.10k	0.033% $ 3.0k
Richard Peters	Lead Independent Director	2yrs	US$148.18k	0.73% $ 68.4k
Lisa Coussens	Member of Scientific Advisory Board	4.7yrs	Nessun dato	Nessun dato
Patricia LoRusso	Member of Scientific Advisory Board	4.7yrs	Nessun dato	Nessun dato
Michael Curran	Member of Scientific Advisory Board	4.7yrs	Nessun dato	Nessun dato
Evan Yu	Member of Scientific Advisory Board	1.8yrs	Nessun dato	Nessun dato
Myriam Chalabi	Member of Scientific Advisory Board	1.8yrs	Nessun dato	Nessun dato

2.0yrs

Durata media

60yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di KANT non è considerato esperto (durata media del mandato 2 anni), il che suggerisce un nuovo consiglio.

Kineta Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

High number of new and inexperienced directors

Kineta, Inc., Annual General Meeting, Jun 21, 2024

Kineta, Inc. Terminates Employment of Shawn Iadonato as CEO

Kineta, Inc. Terminates Employment of Shawn Iadonato as CEO

Kineta, Inc. Announces Board Appointments

No independent directors

Recent updates

TuHURA Biosciences, Inc. (NasdaqCM:HURA) entered into a definitive agreement to acquire Kineta, Inc.

Kineta, Inc. Updates KVA12123 Clinical Results from Ongoing Phase 1/2 Vista101 Study at Society for Immunotherapy of Cancer (2024)

Kineta Announces Completion of Enrollment in the Monotherapy Arm of the VISTA-101 Phase 1 Clinical Study in Advanced Solid Tumors

Kineta, Inc. Announces the Extension of the TuHura Biosciences Exclusivity and Right of First Offer Agreement for KVA12123

Kineta, Inc.(OTCPK:KANT) dropped from S&P TMI Index

Nasdaq Suspends Trading of Kineta's Common Stock Following Denial of Continued Listing Request, Effective September 19, 2024 and to File Form 25-NSE with the Securities and Exchange Commission

Kineta, Inc.(OTCPK:KANT) dropped from NASDAQ Composite Index

Nasdaq Listing Qualifications Staff Denies Kineta, Inc.'s Request for Continued Listing on the Nasdaq Capital Market

Nasdaq Listing Qualifications Staff Denies Kineta, Inc.'s Request for Continued Listing on the Nasdaq Capital Market

Kineta, Inc. Re Opens Enrollment for the Vista-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer

Kineta Receives Written Notice from the Listing Qualifications Department of the Nasdaq Regarding No Longer Complies with the Requirement Under Nasdaq Listing Rule 5550(b)(1)

High number of new and inexperienced directors

Kineta, Inc., Annual General Meeting, Jun 21, 2024

Kineta Receives Written Notice from Nasdaq Regarding Non-Compliance Minimum Closing Bid Price Requirement Under Nasdaq Listing Rule 5550(a)(2)

Kineta, Inc. Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 Vista-101 Clinical Trial

Kineta, Inc. Announces an Update on Its Ongoing Vista-101 Phase 1/2 Clinical Trial Evaluating Kva12123

Kineta, Inc. Terminates Employment of Shawn Iadonato as CEO

Kineta, Inc. Terminates Employment of Shawn Iadonato as CEO

Kineta, Inc. Announces Restructuring and Workforce Reduction

Kineta, Inc. Announces Update on Ongoing Vista-101 Phase 1/2 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Tumor Activity

Kineta, Inc. Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer’s 38th Annual Meeting

Kineta, Inc. Announces First Patient Dosed in Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Combination with KEYTRUDA (Pembrolizumab) in Patients with Advanced Solid Tumors

Kineta, Inc. Announces Positive KVA12123 Monotherapy Safety and Biomarker Data from its Ongoing Phase 1/2 Vista-101 Clinical Trial

New major risk - Share price stability

Kineta Regains Compliance with Nasdaq Listing Rules

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Kineta, Inc. Announces Board Appointments

Third quarter 2022 earnings released

No independent directors

Kineta, Inc. completed the acquisition of Yumanity Therapeutics, Inc. (NasdaqCM:YMTX) from a group of shareholders in a reverse merger transaction.

AMMINISTRATORE DELEGATO

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media